ScholarWorks@중앙대학교

초록

OBJECTIVE: This study aimed to evaluate the clinical efficacy and safety of silodosin in female patients with lower urinary tract symptoms (LUTSs), addressing the limited evidence supporting alpha-blocker use in this population. METHODS: A 12-week, single-arm, prospective, open-label study was conducted from May 2021 to January 2023. Female patients aged over 18 with an International Prostate Symptom Score (IPSS) &#x2265;&#x2009;8 were enrolled and treated with silodosin (8&#x2009;mg once daily). Primary endpoints included changes in IPSS from baseline to 12&#x2009;weeks. Secondary endpoints assessed IPSS quality of life (QOL), Overactive Bladder Symptom Score (OABSS), maximal urinary flow rate (Q max), and residual urine (RU). RESULTS: Ninety-five patients were enrolled, with 85 included in the analysis. After 12&#x2009;weeks, the mean total IPSS significantly decreased from 18.65&#x2009;&#xb1;&#x2009;6.89 at baseline to 12.54&#x2009;&#xb1;&#x2009;5.28 (p&#x2009;<&#x2009;0.001). IPSS-QOL improved from 4.14&#x2009;&#xb1;&#x2009;1.01 to 3.12&#x2009;&#xb1;&#x2009;0.79 (p&#x2009;<&#x2009;0.001). OABSS decreased from 6.89&#x2009;&#xb1;&#x2009;3.41 to 4.28&#x2009;&#xb1;&#x2009;2.39 (p&#x2009;<&#x2009;0.001), and RU reduced from 51.39&#x2009;&#xb1;&#x2009;55.38 to 29.95&#x2009;&#xb1;&#x2009;29.83&#x2009;mL (p&#x2009;<&#x2009;0.001). Q max increased from 13.96&#x2009;&#xb1;&#x2009;6.74 to 16.48&#x2009;&#xb1;&#x2009;6.09&#x2009;mL/s (p&#x2009;<&#x2009;0.001), while voiding volume increased from 163.02&#x2009;&#xb1;&#x2009;70.53 to 176.12&#x2009;&#xb1;&#x2009;47.16&#x2009;mL (p&#x2009;=&#x2009;0.026). Silodosin was well tolerated, with no serious adverse events noted. CONCLUSIONS: Silodosin demonstrates efficacy and safety in treating female patients with moderate-to-severe LUTS, suggesting that it can be considered a viable treatment option alongside established therapies. Further studies are warranted to confirm these findings. © 2024 John Wiley & Sons Australia, Ltd.

키워드